Findings suggest revised atrial fibrillation approach.
Levenson
Deborah
D
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000638:Amiodarone / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000191:economics / Q000401:mortality / Q000628:therapy*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004077:Digoxin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D019468:Disease Management; D004554:Electric Countershock; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D017410:Practice Guidelines as Topic; D013015:Sotalol / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D004077:Digoxin; D013015:Sotalol; D000638:Amiodarone